公开(公告)号：US20080112937A1

公开(公告)日：2008-05-15

申请号：US11632860

申请日：2005-07-19

申请人： Lewis T Williams ,  Hongbing Zhang ,  Srinivas Kothakota ,  Kristen Pierce ,  Pierre Alvaro Beaurang ,  Keting Chu

发明人： Lewis T Williams ,  Hongbing Zhang ,  Srinivas Kothakota ,  Kristen Pierce ,  Pierre Alvaro Beaurang ,  Keting Chu

IPC分类号： A61K48/00 ,  C12N5/08 ,  C12N15/09

CPC分类号： C12N5/0606 ,  A01K2217/05 ,  C12N15/873 ,  C12N2506/00

摘要： Aspects of the present invention relate to compositions and methods of reprogramming a somatic cell to give rise to an autologous embryonic stem cell. These methods involve providing a somatic cell of a donor subject, introducing the somatic cell into an embryo of a recipient subject to produce a chimeric embryo, allowing the chimeric embryo to develop further wherein the somatic cell will reprogram, and then selecting an autologous embryonic stem cell that has developed from the somatic cell. The methods and composition of producing pluripotent embryonic stem cells from a donor's own somatic cells invite the possibility of a number of therapeutic applications, including organ transplant and treatment of autoimmune diseases, cancer, and degenerative disorders such as diabetes, Alzheimer's, and Parkinson's.

摘要翻译： 本发明的方面涉及重编程体细胞以产生自体胚胎干细胞的组合物和方法。 这些方法涉及提供供体受试者的体细胞，将体细胞引入受体的胚胎以产生嵌合胚胎，允许嵌合胚胎进一步发育，其中体细胞将重新编程，然后选择自体胚胎干 从体细胞发育而来的细胞。 从供体自身体细胞细胞产生多能胚胎干细胞的方法和组成可引起许多治疗应用的可能性，包括器官移植和治疗自身免疫性疾病，癌症和退行性疾病如糖尿病，阿尔茨海默病和帕金森病。

公开(公告)号：US20080254033A1

公开(公告)日：2008-10-16

申请号：US10586669

申请日：2005-01-21

申请人： Kristen Pierce ,  Amy L.Tsui Collins ,  Hongbing Zhang ,  Lewis Thomas Williams ,  Pierre Alvaro Beaurang

发明人： Kristen Pierce ,  Amy L.Tsui Collins ,  Hongbing Zhang ,  Lewis Thomas Williams ,  Pierre Alvaro Beaurang

IPC分类号： A61K39/395 ,  A61P25/28 ,  C07K14/435 ,  C12N15/85 ,  C07K16/00 ,  C12N5/10 ,  C12N15/12 ,  A61K31/7105

CPC分类号： C07K14/705

摘要： The present invention provides LRP4, LRP8 and LRP2 (megalin) polypeptides; polynucleotides encoding such; modulators of LRP4, LRP8 and LRP2 activity; and pharmaceutical compositions for the treatment of diseases. Compositions of the invention contain a pharmaceutically acceptable carrier or excipient and at least one modulator that is capable of binding to or interfering with the activity of LRP4, LRP8, LRP2 and active fragments thereof. The invention provides modulators, such as antibodies, RNAi molecules, anti-sense molecules and ribozymes. Additionally, the invention includes methods for the treatment of diseases, such as proliferative diseases and degenerative diseases, and methods of administration of the compositions of the invention.

摘要翻译： 本发明提供LRP4，LRP8和LRP2（巨蛋白）多肽; 编码这样的多核苷酸; LRP4，LRP8和LRP2活性的调节剂; 和用于治疗疾病的药物组合物。 本发明的组合物含有药学上可接受的载体或赋形剂和至少一种能够结合或干扰LRP4，LRP8，LRP2及其活性片段的活性的调节剂。 本发明提供了调节剂，例如抗体，RNAi分子，反义分子和核酶。 另外，本发明包括治疗疾病如增殖性疾病和退行性疾病的方法，以及本发明组合物的施用方法。

公开(公告)号：US20080014594A1

公开(公告)日：2008-01-17

申请号：US10543838

申请日：2004-01-30

申请人： Kevin Hestir ,  Ernestine Lee ,  Keting Chu ,  Yan Wang ,  Kristen Pierce ,  Amy L. Tsui Collins ,  Lewis Thomas Williams

发明人： Kevin Hestir ,  Ernestine Lee ,  Keting Chu ,  Yan Wang ,  Kristen Pierce ,  Amy L. Tsui Collins ,  Lewis Thomas Williams

IPC分类号： G01N33/53

CPC分类号： G01N33/57423 ,  C07K16/40 ,  G01N33/574 ,  G01N2333/70596

摘要： Modulators of phosphatidic acid phosphatase type 2C and other polypeptides, highly expressed in cancers as compared to normal tissues, are provided for treatment of proliferative disorders such as cancer. A method is provided for detecting polypeptides that are overexpressed in cancer, whereby antibodies or binding proteins that specifically recognize these molecules are contacted with a patient's bodily fluid. The method provides an early diagnosis of cancer, and can detect recurrence and metastasis following an initial diagnosis. The invention further provides methods of treating cancer with therapeutic agents directed toward these protein and peptide biomarkers.

摘要翻译： 提供2C型磷脂酸性磷酸酶和与正常组织相比在癌症中高度表达的其它多肽的调节剂用于治疗增殖性疾病如癌症。 提供了用于检测在癌症中过表达的多肽的方法，由此将特异性识别这些分子的抗体或结合蛋白与患者的体液接触。 该方法提供癌症的早期诊断，并且可以在初步诊断后检测复发和转移。 本发明还提供了针对这些蛋白质和肽生物标志物的治疗剂治疗癌症的方法。

公开(公告)号：US20070248605A1

公开(公告)日：2007-10-25

申请号：US10583146

申请日：2004-12-17

申请人： Kevin Hestir ,  Kristen Pierce ,  Lewis Williams ,  Lorianne Masuoka ,  Justin Wong ,  Keting Chu

发明人： Kevin Hestir ,  Kristen Pierce ,  Lewis Williams ,  Lorianne Masuoka ,  Justin Wong ,  Keting Chu

IPC分类号： A61K39/395 ,  C07K16/22 ,  G01N33/53

CPC分类号： C07K16/2863 ,  C07K14/71 ,  G01N33/574 ,  G01N33/74 ,  G01N2333/50 ,  G01N2800/04 ,  G01N2800/065 ,  G01N2800/085 ,  G01N2800/102 ,  G01N2800/104 ,  G01N2800/105 ,  G01N2800/324

摘要： A composition is provided that contains a polypeptide and a modulator or a cell comprising the polypeptide and a modulator, where the modulator specifically interferes with the activity of the polypeptide, and the polypeptide is either FGFR3 or FGFR4, inclusive of all polymorphic forms and variants thereof. The modulator can be an antibody or active fragments thereof, a small molecule drug, an RNAi molecule, an antisense molecule or a ribozyme. A method of treatment of tumors in a subject is also provided where an antagonist of FGFR3 or FGFR4 is administered to the subject.

摘要翻译： 提供了一种组合物，其包含多肽和调节剂或包含该多肽的调节剂和调节剂，其中调节剂特异性干扰多肽的活性，并且该多肽是FGFR3或FGFR4，包括所有多晶型及其变体 。 调节剂可以是抗体或其活性片段，小分子药物，RNAi分子，反义分子或核酶。 还提供了治疗受试者的肿瘤的方法，其中向受试者施用FGFR3或FGFR4的拮抗剂。

公开(公告)号：US20100183620A1

公开(公告)日：2010-07-22

申请号：US12626534

申请日：2009-11-25

申请人： KAUMUDI BHAWE ,  Elizabeth Bosch ,  Kathleen Boyle ,  Arthur Brace ,  Anuk Das ,  Francis Farrell ,  Pitchumani Sivakumar ,  Jeffrey Finer ,  Kristen Pierce ,  Kathleen M. Sullivan ,  Brian Wong

发明人： KAUMUDI BHAWE ,  Elizabeth Bosch ,  Kathleen Boyle ,  Arthur Brace ,  Anuk Das ,  Francis Farrell ,  Pitchumani Sivakumar ,  Jeffrey Finer ,  Kristen Pierce ,  Kathleen M. Sullivan ,  Brian Wong

IPC分类号： A61K39/395 ,  A61K31/7088 ,  A61K38/02 ,  A61K38/16 ,  A61P21/00 ,  C12Q1/68

CPC分类号： C07K14/811 ,  A61K38/57 ,  C07K16/38 ,  C07K2317/76

摘要： The invention encompasses methods and compositions for increasing or decreasing collagen 1A1 expression and/or α-smooth muscle actin expression in lung fibroblasts using SERPINE2 and antagonists of SERPINE2. The invention also encompasses methods and compositions for increasing or decreasing the formation of myofibroblasts. The invention further provides methods and compositions for treatment of lung diseases, such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.

摘要翻译： 本发明包括使用SERPINE2和SERPINE2拮抗剂增加或减少肺成纤维细胞中胶原1A1表达和/或α-平滑肌肌动蛋白表达的方法和组合物。 本发明还包括用于增加或减少肌成纤维细胞形成的方法和组合物。 本发明进一步提供了治疗肺部疾病如特发性肺纤维化和慢性阻塞性肺疾病的方法和组合物。